Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Caterina Giovannini.
World Journal of Biological Psychiatry | 2010
Luisella Bocchio-Chiavetto; Vincenzo Bagnardi; Roberta Zanardini; Raffaella Molteni; Maria Gabriela Nielsen; Anna Placentino; Caterina Giovannini; Luciana Rillosi; Mariacarla Ventriglia; Marco Riva; Massimo Gennarelli
Abstract Objectives. Alterations of BDNF signalling in major depression (MD) are supported by studies demonstrating decreased levels of the neurotrophin serum and plasma content in MD patients. We conducted a replication study and we performed two meta-analyses on studies analysing serum and plasma BDNF levels in MD patients. Methods. The samples were composed by 489 patients/483 controls for the meta-analysis on serum and by 161 patients/211 controls for that on plasma levels. We performed also subgroup analyses to examine whether the decrease in BDNF levels in MD was influenced by gender. Results. In the replication study we found decreased serum BDNF levels in MD patients (P<0.01) and we demonstrated that is down-regulated the mature form of the neurotrophin (mBDNF). No significant difference was evidenced for plasma BDNF levels. The meta-analyses showed a reduction of both BDNF serum (P<0.0001) and plasma levels (P=0.02) in MD. No difference in the effect size on serum BDNF was observed between males and females (P=0.18). Conclusions. In conclusion, our results provide evidence of peripheral BDNF alteration in MD and support the rationale for further investigation aiming to the identification of biomarkers for differential diagnosis and personalization of therapies in this disorder.
Pharmacogenomics Journal | 2009
Rudolf Uher; P Huezo-Diaz; Nader Perroud; Robert Peter Smith; Marcella Rietschel; Ole Mors; Joanna Hauser; Wolfgang Maier; Dejan Kozel; Neven Henigsberg; Mara Isabel Barreto; Anna Placentino; Mojca Zvezdana Dernovšek; Thomas G. Schulze; Petra Kalember; Astrid Zobel; Piotr M. Czerski; Erik Roj Larsen; Daniel Souery; Caterina Giovannini; Jonathon Gray; Cathryn M. Lewis; Anne Farmer; Katherine J. Aitchison; Peter McGuffin; Ian Craig
The objective of the Genome-based Therapeutic Drugs for Depression study is to investigate the function of variations in genes encoding key proteins in serotonin, norepinephrine, neurotrophic and glucocorticoid signaling in determining the response to serotonin-reuptake-inhibiting and norepinephrine-reuptake-inhibiting antidepressants. A total of 116 single nucleotide polymorphisms in 10 candidate genes were genotyped in 760 adult patients with moderate-to-severe depression, treated with escitalopram (a serotonin reuptake inhibitor) or nortriptyline (a norepinephrine reuptake inhibitor) for 12 weeks in an open-label part-randomized multicenter study. The effect of genetic variants on change in depressive symptoms was evaluated using mixed linear models. Several variants in a serotonin receptor gene (HTR2A) predicted response to escitalopram with one marker (rs9316233) explaining 1.1% of variance (P=0.0016). Variants in the norepinephrine transporter gene (SLC6A2) predicted response to nortriptyline, and variants in the glucocorticoid receptor gene (NR3C1) predicted response to both antidepressants. Two HTR2A markers remained significant after hypothesis-wide correction for multiple testing. A false discovery rate of 0.106 for the three strongest associations indicated that the multiple findings are unlikely to be false positives. The pattern of associations indicated a degree of specificity with variants in genes encoding proteins in serotonin signaling influencing response to the serotonin-reuptake-inhibiting escitalopram, genes encoding proteins in norepinephrine signaling influencing response to the norepinephrine-reuptake-inhibiting nortriptyline and a common pathway gene influencing response to both antidepressants. The single marker associations explained only a small proportion of variance in response to antidepressants, indicating a need for a multivariate approach to prediction.
British Journal of Psychiatry | 2009
Rudolf Uher; Wolfgang Maier; Joanna Hauser; Andrej Marusic; Christine Schmael; Ole Mors; Neven Henigsberg; Daniel Souery; Anna Placentino; Marcella Rietschel; Astrid Zobel; Monika Dmitrzak-Weglarz; Ana Petrovic; Lisbeth Jorgensen; Petra Kalember; Caterina Giovannini; Mara Isabel Barreto; Amanda Elkin; Sabine Landau; Anne Farmer; Katherine J. Aitchison; Peter McGuffin
BACKGROUND Tricyclic antidepressants and serotonin reuptake inhibitors are considered to be equally effective, but differences may have been obscured by internally inconsistent measurement scales and inefficient statistical analyses. AIMS To test the hypothesis that escitalopram and nortriptyline differ in their effects on observed mood, cognitive and neurovegetative symptoms of depression. METHOD In a multicentre part-randomised open-label design (the Genome Based Therapeutic Drugs for Depression (GENDEP) study) 811 adults with moderate to severe unipolar depression were allocated to flexible dosage escitalopram or nortriptyline for 12 weeks. The weekly Montgomery-Asberg Depression Rating Scale, Hamilton Rating Scale for Depression, and Beck Depression Inventory were scored both conventionally and in a more novel way according to dimensions of observed mood, cognitive symptoms and neurovegetative symptoms. RESULTS Mixed-effect linear regression showed no difference between escitalopram and nortriptyline on the three original scales, but symptom dimensions revealed drug-specific advantages. Observed mood and cognitive symptoms improved more with escitalopram than with nortriptyline. Neurovegetative symptoms improved more with nortriptyline than with escitalopram. CONCLUSIONS The three symptom dimensions provided sensitive descriptors of differential antidepressant response and enabled identification of drug-specific effects.
European Neuropsychopharmacology | 2013
Luisella Bocchio-Chiavetto; Elisabetta Maffioletti; Paola Bettinsoli; Caterina Giovannini; Stefano Bignotti; Daniela Tardito; Dario Corrada; Luciano Milanesi; Massimo Gennarelli
MicroRNAs (miRNAs) are potent modulators of protein expression that play key roles in brain pathways regulating neurogenesis and synaptic plasticity. These small RNAs may be critical for the pathophysiology of mental disorders and may influence the effectiveness of psychotropic drugs. To investigate the possible involvement of miRNAs in the mechanism of action of antidepressants (AD), we conducted a whole-miRNome quantitative analysis with qRT-PCR of the changes in the blood of 10 depressed subjects after 12 weeks of treatment with escitalopram. Thirty miRNAs were differentially expressed after the AD treatment: 28 miRNAs were up-regulated, and 2 miRNAs were strongly down-regulated. miRNA target gene prediction and functional annotation analysis showed that there was a significant enrichment in several pathways associated with neuronal brain function (such as neuroactive ligand-receptor interaction, axon guidance, long-term potentiation and depression), supporting the hypothesis that the differentially regulated miRNAs may be involved in the AD mechanism.
Journal of Psychopharmacology | 2012
P Huezo-Diaz; Nader Perroud; Edgar P. Spencer; Robert Peter Smith; Sarah Sim; Susanne Virding; Rudolf Uher; Cerisse Gunasinghe; Jonathon Gray; Desmond D. Campbell; Joanna Hauser; Wolfgang Maier; Andrej Marusic; Marcella Rietschel; Jorge Perez; Caterina Giovannini; Ole Mors; Julien Mendlewicz; Peter McGuffin; Anne Farmer; Magnus Ingelman-Sundberg; Ian Craig; Katherine J. Aitchison
In vitro work shows CYP2C19 and CYP2D6 contribute to the metabolism of escitalopram to its primary metabolite, N-desmethylescitalopram. We report the effect of CYP2C19 and CYP2D6 genotypes on steady state morning concentrations of escitalopram and N-desmethylescitalopram and the ratio of this metabolite to the parent drug in 196 adult patients with depression in GENDEP, a clinical pharmacogenomic trial. Subjects who had one CYP2D6 allele associated with intermediate metabolizer phenotype and one associated with poor metabolizer (i.e. IM/PM genotypic category) had a higher mean logarithm escitalopram concentration than CYP2D6 extensive metabolizers (EMs) (p = 0.004). Older age was also associated with higher concentrations of escitalopram. Covarying for CYP2D6 and age, we found those homozygous for the CYP2C19*17 allele associated with ultrarapid metabolizer (UM) phenotype had a significantly lower mean escitalopram concentration (2-fold, p = 0.0001) and a higher mean metabolic ratio (p = 0.0003) than EMs, while those homozygous for alleles conferring the PM phenotype had a higher mean escitalopram concentration than EMs (1.55-fold, p = 0.008). There was a significant overall association between CYP2C19 genotypic category and escitalopram concentration (p = 0.0003; p = 0.0012 Bonferroni corrected). In conclusion, we have demonstrated an association between CYP2C19 genotype, including the CYP2C19*17 allele, and steady state escitalopram concentration.
Journal of Psychopharmacology | 2011
Robert Keers; Cristian Bonvicini; Catia Scassellati; Rudolf Uher; Anna Placentino; Caterina Giovannini; Marcella Rietschel; Neven Henigsberg; Dejan Kozel; Ole Mors; Wolfgang Maier; Joanna Hauser; Daniel Souery; Julien Mendlewicz; Christine Schmäl; Astrid Zobel; Erik Roj Larsen; Aleksandra Szczepankiewicz; Zrnka Kovačić; Amanda Elkin; Ian Craig; Peter McGuffin; Anne Farmer; Katherine J. Aitchison; Massimo Gennarelli
There is substantial inter-individual variation in response and adverse reactions to antidepressants, and genetic variation may, in part, explain these differences. GNB3 encodes the β3 subunit of the G protein complex, which is involved in the downstream signalling cascade following monoamine receptor activation. A functional polymorphism in this gene (C825T) has been associated with response to antidepressants. Several lines of evidence suggest that GNB3 moderates improvement in the neurovegetative symptoms of depression (such as sleep and appetite) and related adverse reactions independently of change in core mood symptoms. We here report analysis of data from GENDEP, a part-randomized pharmacogenomic trial, on the outcome of 811 subjects with major depression undergoing treatment with either escitalopram or nortriptyline in which the C825T SNP and three further SNPs in GNB3 were genotyped. The TT genotype was significantly associated with a superior response to nortriptyline and these effects were specific to improvements in neurovegetative symptoms. In addition, the same genotype predicted fewer incidents of treatment-emergent insomnia and greater weight gain on the same drug. Our results are consistent with previous associations with GNB3 and emphasize the importance of signalling genes in antidepressant response.
BMC Medicine | 2009
Nader Perroud; Rudolf Uher; Andrej Marusic; Marcella Rietschel; Ole Mors; Neven Henigsberg; Joanna Hauser; Wolfgang Maier; Daniel Souery; Anna Placentino; Aleksandra Szczepankiewicz; Lisbeth Jorgensen; Jana Strohmaier; Astrid Zobel; Caterina Giovannini; Amanda Elkin; Cerisse Gunasinghe; Joanna Gray; Desmond D. Campbell; Bhanu Gupta; Anne Farmer; Peter McGuffin; Katherine J. Aitchison
BackgroundSuicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors of emergence and worsening of suicidal ideation during tricyclic antidepressant and serotonin reuptake inhibitor treatment.MethodsIn a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal ideation at baseline.ResultsSuicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram, respectively. Retirement and history of suicide attempts predicted TWOSI.ConclusionIncreases in suicidal ideation were associated with depression severity and decreased during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation beyond the initial weeks of antidepressant treatment.Trial registrationEudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).
Journal of Affective Disorders | 2010
Robert Keers; Rudolf Uher; Bhanu Gupta; Marcella Rietschel; Thomas G. Schulze; Joanna Hauser; Maria Skibinska; Neven Henigsberg; Petra Kalember; Wolfgang Maier; Astrid Zobel; Ole Mors; Ann Suhl Kristensen; Dejan Kozel; Caterina Giovannini; Julien Mendlewicz; Sudhir Kumar; Peter McGuffin; Anne Farmer; Katherine J. Aitchison
BACKGROUND The occurrence of stressful life events (SLEs) has been shown to predict response to antidepressants; however, results are inconsistent. There is some evidence to suggest that SLEs prior to treatment are associated with greater cognitive symptoms at baseline and may therefore predict changes in these symptoms specifically. METHODS GENDEP, a prospective part-randomised pharmacogenomics trial, collected longitudinal data on the symptoms of patients with major depression treated with either a selective serotonin reuptake inhibitor (SSRI, escitalopram) or a tricyclic antidepressant (TCA, nortriptyline). Data on life events experienced in the 6 months preceding treatment measured using the List of Threatening Experiences Questionnaire (LTE-Q) were available for 728 participants. RESULTS Both the occurrence and number of SLEs were associated with greater cognitive but not mood or neurovegetative symptoms prior to treatment. Those who reported SLEs also experienced a greater decline in cognitive symptoms during treatment with escitalopram, but not with nortriptyline. LIMITATIONS Life events were measured retrospectively using a self-report checklist and are therefore subject to a number of biases especially in the context of depressive illness. CONCLUSIONS These findings are in line with cognitive theories of depression and suggest that symptomatic heterogeneity may have contributed to inconsistencies in studies reported to date. Our results also tentatively suggest a clinically relevant drug specific effect of SLEs. Specifically, those reporting stress may benefit more from treatment with SSRIs than TCAs.
Journal of Affective Disorders | 2010
Nader Perroud; Rudolf Uher; Joanna Hauser; Marcella Rietschel; Neven Henigsberg; Anna Placentino; Dejan Kozel; Wolfgang Maier; Ole Mors; Daniel Souery; Monika Dmitrzak-Weglarz; Lisbeth Jorgensen; Zrnka Kovačić; Caterina Giovannini; Julien Mendlewicz; Astrid Zobel; Jana Strohmaier; Peter McGuffin; Katherine J. Aitchison; Anne Farmer
BACKGROUND It has been proposed that a history of suicide attempts could be a correlate of severe depressive disorder and that suicide attempters (SA) could represent a particular subtype of subjects suffering from major depressive disorder. We investigated clinical and demographic characteristics associated with SA and tested the hypothesis that a history of suicide attempts predicts poor response to antidepressants. METHODS One-hundred-and-forty-one SA and 670 non-SA subjects with major depressive disorder (MDD) were treated for twelve weeks with escitalopram or nortriptyline in GENDEP, a part-randomized multi-center clinical and pharmacogenetic study. Baseline characteristics were compared using linear and logistic regression. Linear mixed models were used to analyse continuous outcomes during the twelve weeks of follow-up. RESULTS At baseline, SA subjects suffered from more severe depression (mean Montgomery-Asberg Depression Rating Scale: 30.29 (7.61) vs 28.43 (6.54), p=0.0002), reported higher level of suicidal ideation (1.21 (0.82) vs 0.73 (0.48), p<0.0001), had a younger age of onset and experienced more depressive episodes, had higher harm avoidance scores and poorer socio-demographic environment than non-SA individuals. However, during the twelve weeks of treatment and after adjustment for baseline severity of depression there was no difference in treatment response between SA and non-SA. LIMITATIONS Due to its retrospective design, it is possible that more severely depressed subjects might report more suicide attempts than less depressed individuals. CONCLUSIONS While SA differed from non-SA in several clinical and demographic characteristics, the antidepressants were similarly effective in SA as in comparably severely depressed subjects without a history of suicide attempts.
Psychiatric Services | 2009
Laura Pedrini; Laura Rosa Magni; Caterina Giovannini; Valentina Panetta; Valeria Zacchi; Giuseppe Rossi; Anna Placentino
OBJECTIVE This study evaluated levels and risk factors of burnout in a sample of mental health professionals employed in nonhospital psychiatric residential facilities of northern Italy. METHODS Nurses, nurse assistants, and educators completed a questionnaire evaluating demographic variables, burnout (Maslach Burnout Inventory), job characteristics (Job Diagnostic Survey), workload, relationships with colleagues, and support from supervising coordinators. A total of 202 (83% response rate) questionnaires were analyzed. Logistic linear regressions were used to estimate predictors of burnout dimensions. RESULTS Burnout risk was widespread. Low feedback about job performance, poor support from coordinators, and young age predicted emotional exhaustion. Low feedback about job performance predicted feelings of depersonalization. Low task identity and young age predicted reduced feelings of personal accomplishment. CONCLUSIONS Interventions to prevent burnout among employees should be developed. These include providing feedback about performance, clearly identifying the tasks of the job, and providing support.